Radiopharm Achieves Nasdaq Listing of American Depositary Shares
Radiopharm Theranostics announces the listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market under the ticker symbol RADX, effective November 27, 2024. Each ADS represents 300 ordinary shares, complementing the company's primary ASX listing. The Nasdaq listing was achieved without an associated capital raise, with Deutsche Bank Trust Company Americas appointed as depositary. Currently, 21% of Radiopharm's shareholders are US-based. The company expects initial trading volume may be as existing shareholders convert ordinary shares to ADSs.
Radiopharm Theranostics annuncia la quotazione delle sue American Depositary Shares (ADS) sul Nasdaq Capital Market con il simbolo ticker RADX, a partire dal 27 novembre 2024. Ogni ADS rappresenta 300 azioni ordinarie, integrando la quotazione principale dell'azienda sull'ASX. La quotazione sul Nasdaq è stata effettuata senza un aumento di capitale associato, con Deutsche Bank Trust Company Americas nominata custode. Attualmente, il 21% degli azionisti di Radiopharm è situato negli Stati Uniti. L'azienda si aspetta che il volume iniziale degli scambi possa aumentare man mano che gli azionisti esistenti convertono le azioni ordinarie in ADS.
Radiopharm Theranostics anuncia la inclusión de sus American Depositary Shares (ADS) en el Nasdaq Capital Market bajo el símbolo de cotización RADX, a partir del 27 de noviembre de 2024. Cada ADS representa 300 acciones ordinarias, complementando la cotización principal de la empresa en la ASX. La inclusión en Nasdaq se realizó sin un aumento de capital asociado, con Deutsche Bank Trust Company Americas designada como depositaria. Actualmente, el 21% de los accionistas de Radiopharm están basados en EE. UU. La empresa espera que el volumen inicial de negociación pueda incrementarse a medida que los accionistas existentes conviertan acciones ordinarias en ADS.
Radiopharm Theranostics는 Nasdaq Capital Market에 RADX라는 티커 기호로 2024년 11월 27일부터 미국예금주식(ADS)을 상장한다고 발표했습니다. 각 ADS는 300개의 보통주를 나타내며, 회사의 주요 ASX 상장을 보완합니다. Nasdaq 상장은 자본 증가 없이 이루어졌으며, Deutsche Bank Trust Company Americas가 예탁회사로 지정되었습니다. 현재 Radiopharm의 주주 중 21%가 미국에 있습니다. 회사는 기존 주주가 보통주를 ADS로 전환함에 따라 초기 거래량이 증가할 것으로 예상하고 있습니다.
Radiopharm Theranostics annonce la cotation de ses American Depositary Shares (ADS) sur le Nasdaq Capital Market sous le symbole boursier RADX, à compter du 27 novembre 2024. Chaque ADS représente 300 actions ordinaires, complétant la cotation principale de la société sur l'ASX. La cotation sur le Nasdaq a été réalisée sans augmentation de capital associée, avec Deutsche Bank Trust Company Americas désignée comme dépositaire. Actuellement, 21 % des actionnaires de Radiopharm sont basés aux États-Unis. L'entreprise s'attend à ce que le volume de négociation initial puisse augmenter à mesure que les actionnaires existants convertissent des actions ordinaires en ADS.
Radiopharm Theranostics gibt die Notierung seiner American Depositary Shares (ADS) an der Nasdaq Capital Market unter dem Tickersymbol RADX bekannt, die am 27. November 2024 in Kraft tritt. Jede ADS repräsentiert 300 Stammaktien und ergänzt die Hauptnotierung des Unternehmens an der ASX. Die Nasdaq-Notierung wurde ohne eine damit verbundene Kapitalerhöhung erreicht, wobei die Deutsche Bank Trust Company Americas als Depotbank benannt wurde. Derzeit befinden sich 21 % der Aktionäre von Radiopharm in den USA. Das Unternehmen erwartet, dass das anfängliche Handelsvolumen steigen könnte, wenn bestehende Aktionäre ihre Stammaktien in ADS umwandeln.
- Successfully secured Nasdaq listing, expanding market access and visibility
- 21% existing US shareholder base provides foundation for US market presence
- No dilutive capital raising associated with the listing
- Initial trading volume may be due to ADS conversion process
- Additional administrative and compliance costs associated with Nasdaq listing
Insights
The Nasdaq listing marks a significant strategic move for Radiopharm Theranostics, providing enhanced access to U.S. capital markets and potentially broader investor exposure. While there's no immediate capital raising, the secondary listing creates a more liquid trading platform for U.S. investors through ADSs, with each representing 300 ordinary shares. The 21% existing U.S. shareholder base suggests established interest, though initial trading volume may be constrained as shareholders convert ordinary shares to ADSs.
The listing structure via ADRs with Deutsche Bank as depositary minimizes immediate dilution risks while positioning for future capital access. However, investors should note additional compliance costs and administrative overhead associated with dual-listing requirements. The strategic timing and no-raise approach indicate confidence in current capital position while laying groundwork for future growth opportunities in the world's largest biotech market.
- Trading under ticker symbol RADX
- Complements existing US shareholders (currently holding
21% of Radiopharm) - No associated capital raising
- Modest admin & financial compliance overheads
SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that American Depositary Shares (“ADSs”) representing its ordinary shares will commence trading on the Nasdaq Capital Market (“Nasdaq”) on Wednesday morning, 27 November 2024 US time, under the ticker symbol “RADX”. Each ADS represents 300 ordinary shares of the Company.
The listing on Nasdaq follows the declaration of effectiveness by the U.S. Securities and Exchange Commission (“SEC”) of the Company's registration statement on Form 20-F and formal approval from Nasdaq upon meeting its listing requirements. The Nasdaq listing is a secondary listing and complements the Company’s existing primary listing of ordinary shares on the ASX.
The Company completed the Nasdaq listing without an associated capital raise in the United States. Therefore, initial trading of ADSs may be limited due to the time it takes for existing shareholders to deposit their RAD ordinary shares into the ADR program and receive ADSs for trading on Nasdaq. Deutsche Bank Trust Company Americas has been appointed depositary, custodian, and registrar for the Company's American Depositary Receipt program.
"Listing on Nasdaq is a very important strategic milestone for Radiopharm that will help increase our visibility with U.S. and international investors," said Riccardo Canevari, CEO and Managing Director of Radiopharm.
More information regarding the process to deposit the ordinary shares into the ADR program and receive ADSs is included in the Company’s announcement made to the ASX on 19 September 2024.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a deep pipeline of highly differentiated molecules spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumour cancers including brain, lung, breast and pancreas. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
FAQ
When will Radiopharm (RADX) begin trading on Nasdaq?
How many ordinary shares does each Radiopharm (RADX) ADS represent?
What percentage of Radiopharm (RADX) shareholders are US-based?
Did Radiopharm (RADX) raise capital with its Nasdaq listing?
